MIG Capital Partners with CoreMedic for Series B Extension Funding

MIG Capital AG and CoreMedic GmbH have announced new funding for CoreMedic’s Series B extension. This round supports the ChordArt transcatheter mitral valve repair device, a minimally invasive alternative to traditional surgery. CoreMedic aims to leverage this funding to complete its First-in-human study, crucial for advancing clinical development.

MIG Capital, a leading venture firm, joins an international syndicate of medtech investors. Matthias Guth from MIG Capital highlights CoreMedic’s innovative approach to cardiovascular treatments. ChordArt addresses Mitral Valve Regurgitation, a condition affecting over 24 million people globally. Its minimally invasive technology offers hope to patients unable to undergo open-heart surgery.

The new investments will enable CoreMedic to expand its clinical programs globally. This partnership marks a significant milestone in the company's development, facilitating progress towards broader accessibility of innovative heart valve repair options.